RAMSEY, N.J. and BOCA RATON, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the…
NEWTOWN, Pa., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW) (“Traws” or “Traws Pharma”), a clinical stage…
Cash and cash equivalents of $131.9M as of December 31, 2024 Cash runway extends through anticipated topline data readouts of…
Generated record quarterly net revenues of $190.6 million, representing year-over-year growth of 44.8%Total Rare Disease quarterly net revenue of $87.0…
Reports record fourth quarter 2024 total revenue of $8.2 million, representing 30% growth compared to fourth quarter 2023; recurring revenue…
Reported promising safety and preliminary efficacy data for REC-617, an oral CDK7 inhibitor, and met primary endpoints and demonstrated encouraging…
LONDON, MADRID, and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a Kyowa Kirin company, announced it has recently…
Daridorexant is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as…
Leiden, the Netherlands, February 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in…
Building on success across its three clinical programs, Avidity is leading in rare neuromuscular diseases with a strong balance sheet…